Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

LAVAL, QC, Oct. 6, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its third-quarter 2021 financial results on Tuesday, Nov. 2, 2021. Bausch Health will host a conference call and live web cast at 8:00 a.m.

Bausch Health Companies Inc. Will Release Third-Quarter 2021 Financial Results On November 2

Bausch Health (BHC) achieves study endpoints in the phase III study evaluating its investigational drug NOV03 in patients with DED associated with MGD.

Bausch's (BHC) NOV03 for Dry Eye Disease Meets Study Goal

LAVAL, QC and HEIDELBERG, Germany, Sept. 30, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Novaliq GmbH ("Novaliq"), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced statistically significant topline data from the second Phase 3 (MOJAVE) trial evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).

Bausch + Lomb Announces Statistically Significant Topline Results from the Second Phase 3 Trial Of NOV03 (perfluorohexyloctane) in Dry Eye Disease Associated with Meibomian Gland Dysfunction

LAVAL, QC, Sept. 29, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today released its annual Environmental, Social and Governance (ESG) Report (previously referred to as the "Corporate Social Responsibility" or "CSR" Report), highlighting the Company's ongoing commitment to drive a sustainable and equitable impact for its various stakeholders.

Bausch Health Releases Annual Environmental, Social and Governance Report

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Bausch Health (BHC) is a Top-Ranked Value Stock: Should You Buy?

Bausch (BHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Bausch (BHC) Surges 8%: Is This an Indication of Further Gains?

One analyst crunches the numbers to come up with a share price valuation well above current levels.

Why Bausch Health Companies Stock Zoomed 8% Higher Today

Biogen

BioNTech SE

CRISPR Therapeutics

Moderna

Pfizer

Teva Pharmaceutical

Vertex Pharmaceuticals

Viatris

SPDR S&P Pharmaceuticals ETF

With drug pricing reform on the horizon, investors may want to analyze their allocation.

Is Now the Time to Ditch Pharma Stocks?

Morgan Stanley

Bausch Health Companies, Inc. (BHC) CEO Joseph Papa on Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)

Bausch Health Cos. Inc. BHC, -0.59% said Monday it has filed confidentially for the initial public offerings of its eye health business Bausch & Lomb, and its medical aesthetics business Global Solta.

Bausch Health files confidentially for IPOs of eye care business and medical aesthetics business

Reuters reports that Bausch Health Companies Inc (NYSE: BHC) will pay $300 million to settle an antitrust lawsuit related to illegally maintaining a monopoly on diabetes drug Glumetza. The FDA first approved Glumetza, a once-daily extended-release version of metformin, owned by Depomed, now known as Assertio Holdings Inc (NASDAQ: ASRT), and Santarus, which Bausch later acquired.

Bausch Pays $300M For Diabetes Drug Lawsuit: Reuters

Bausch (BHC) reported earnings 30 days ago. What's next for the stock?

Why Is Bausch (BHC) Up 15.2% Since Last Earnings Report?

Data to Feature New Health Economic Outcomes Research of Treatment of Emergency Department Patients with Opioid-Induced Constipation LAVAL, QC, Sept. 2, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, today announced that new Health Economic Outcomes Research (HEOR) data featuring RELISTOR® (methylnaltrexone bromide) will be shared at PAINWeek 2021 taking place in Las Vegas from Sept.

Salix Will Share RELISTOR® (Methylnaltrexone Bromide) Data At PAINWeek 2021

Activists are circling the company and pressuring to unlock shareholder value. Stock still looks attractive from a valuation and near-term catalyst standpoint.

Activist Spotlight: Activists In Bausch Health With Catalysts On Horizon

Amphastar Pharma

Dr. Reddy's Labs

The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.

3 Generic Drug Stocks to Watch Amid Pandemic & Pricing Pressure

BHC fell after posting quarterly earnings.

Why Bausch Health Stock Is On Sale Again

Bausch (BHC) beats on earnings but misses on sales in the second quarter. The company also lowers its annual revenue guidance.

Bausch's (BHC) Q2 Earnings Beat Estimates, Revenues Miss

The turnaround isn't happening as fast as investors expected.

Why Bausch Health Companies Is Plunging Today

Bausch (BHC) delivered earnings and revenue surprises of 1.03% and -0.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Bausch Health (BHC) Tops Q2 Earnings Estimates

Bausch Health Companies, Inc. (BHC) CEO Joseph Papa on Q2 2021 Results - Earnings Call Transcript

Bausch Health Companies Inc (NYSE: BHC) has reported Q2 revenues of $2.1 billion, +26% Y/Y, and missing the consensus of $2.12 billion. Revenue increased organically by $380 million, or 23% Y/Y.

Bausch Health Misses On Q2 Sales, Cuts FY21 Outlook, Plans IPO For Medical Aesthetics Business

Bausch Health Companies Inc. shares fell 6% in premarket trade Tuesday, after the company posted a surprise loss in the second quarter, hurt by higher costs stemming from litigation, selling, general and administration expenses and the impact of a recall caused by a quality issue at a third-party supplier. The loss came to $595 million, or $1.66 a share, wider than the loss of $326 million, or 92 cents a share, posted in the year-earlier period.

Bausch Health shares slide 6% premarket after surprise loss, says will seek IPO of Solta Medical business

LAVAL, Quebec, Aug. 3, 2021 /PRNewswire/ -- Second-Quarter 2021 Financial Results Revenues of $2.100 Billion GAAP Net Loss of $595 Million Adjusted EBITDA (non-GAAP) 1  of $826 Million GAAP Cash Generated from Operations of $395 Million Thomas J. Appio Appointed CEO of Bausch Pharma 2   Bausch Health Announced Plans to Pursue an Initial Public Offering for Solta Medical 3 Revised 2021 Full-Year Revenue and Adjusted EBITDA (non-GAAP) Guidance Ranges, Primarily to Reflect Amoun Pharmaceutical Divestiture Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company" or "we") today announced its second-quarter 2021 financial results.

Bausch Health Companies Inc. Announces Second-Quarter 2021 Results

IPO Would Unlock Value in a Medical Aesthetics Leader Transaction Will Enable Bausch Health to Continue to Execute on its Previously Announced Spinoff of its Bausch + Lomb Eye Health Business LAVAL, QC, Aug. 3, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that it plans to pursue an initial public offering (IPO) of its Solta Medical business ("Solta"). Solta is a leading global provider in medical aesthetics with innovative and effective skin rejuvenation and body contouring solutions, including the Thermage® RF systems, Fraxel® laser, Clear + Brilliant® laser and VASER® ultrasonic systems.

Bausch Health Announces Plans To Pursue An Initial Public Offering Of Solta Medical

LAVAL, Quebec, Aug. 3, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it will reduce debt by $350 million through the redemption of outstanding senior notes, using cash on hand and cash generated from operations. Bausch Health will redeem $350 million aggregate principal amount of its outstanding 6.125% Senior Notes due 2025, CUSIP Nos.

News for Bausch Health Companies Inc Stock (BHC)